Ombitasvir/paritaprevir/ritonavir - AbbVie/Enanta Pharmaceuticals
Alternative Names: ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); VIEKIRA XR; ViekiraxLatest Information Update: 27 Sep 2021
At a glance
- Originator Enanta Pharmaceuticals
- Developer AbbVie
- Class Amides; Anilides; Antiretrovirals; Antivirals; Aza compounds; Carbamates; Cyclopropanes; Phenanthridines; Pyrroles; Pyrrolidines; Small molecules; Sulfones; Thiazoles
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 27 Sep 2021 No development reported - Phase-III for Hepatitis C (Combination therapy) in Brazil (PO)
- 27 Sep 2021 No development reported - Phase-III for Hepatitis C (Combination therapy) in China (PO)
- 27 Sep 2021 No development reported - Phase-III for Hepatitis C (Combination therapy) in South Korea (PO)